These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 19199267)

  • 1. An improved prognostic parameter for non-Hodgkin's lymphoma based on the combination of three serum tumor markers.
    Gui W; Wang T; Wang J; Wang L; He J; Yang B; Zhao Z; Zhang H; Zhang Q
    Int J Biol Markers; 2008; 23(4):207-13. PubMed ID: 19199267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new serologic index for low-grade non-Hodgkin's lymphoma based on initial CA125 and LDH serum levels.
    Benboubker L; Valat C; Linassier C; Cartron G; Delain M; Bout M; Fetissof F; Lefranq T; Lamagnere JP; Colombat P
    Ann Oncol; 2000 Nov; 11(11):1485-91. PubMed ID: 11142490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum CA 125 as a prognostic factor in non-Hodgkin's lymphoma.
    Bairey O; Blickstein D; Stark P; Prokocimer M; Nativ HM; Kirgner I; Shaklai M
    Leuk Lymphoma; 2003 Oct; 44(10):1733-8. PubMed ID: 14692526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma.
    Bonnet C; Beguin Y; Fassotte MF; Seidel L; Luyckx F; Fillet G
    Eur J Haematol; 2007 May; 78(5):399-404. PubMed ID: 17419741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of serum beta-2 microglobulin in patients with non-Hodgkin lymphoma.
    Wu L; Wang T; Gui W; Lin H; Xie K; Wang H; Gao T; Zhang X; Liu L; Han T; Tian Y; Hou L
    Oncology; 2014; 87(1):40-7. PubMed ID: 24969158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma: correlation with tumor parameters and disease activity.
    Lazzarino M; Orlandi E; Klersy C; Astori C; Brusamolino E; Corso A; Bellio L; Gargantini L; Morra E; Bernasconi C
    Cancer; 1998 Feb; 82(3):576-82. PubMed ID: 9452277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.
    Warzocha K; Salles G; Bienvenu J; Bastion Y; Dumontet C; Renard N; Neidhardt-Berard EM; Coiffier B
    J Clin Oncol; 1997 Feb; 15(2):499-508. PubMed ID: 9053471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum CA125: a tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin's lymphoma.
    Zidan J; Hussein O; Basher W; Zohar S
    Oncologist; 2004; 9(4):417-21. PubMed ID: 15266095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical significance of serum lactate dehydrogenase, β2-microglobulin and vascular endothelial growth factor level detection in patients with non-Hodgkin's lymphoma].
    Duan Y; Li G; Hu HX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):608-10. PubMed ID: 22739165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of the epithelial tumor marker CA-125 in non-Hodgkin's lymphoma.
    Ozgüroglu M; Turna H; Demir G; Döventas A; Demirelli F; Mandel NM; Büyükünal E; Serdengeçti S; Berkarda B
    Am J Clin Oncol; 1999 Dec; 22(6):615-8. PubMed ID: 10597748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The biological markers of non-Hodgkin's lymphomas: their role in diagnosis, prognostic assessment and therapeutic strategy.
    Morra E
    Int J Biol Markers; 1999; 14(3):149-53. PubMed ID: 10569136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical value of combined detection of LDH, TPS, CEA and beta2-MG in patients with non- Hodgkin's lymphoma].
    Chen W; Luo RC; Fan WW; Ma SD
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Feb; 26(2):227-8, 230. PubMed ID: 16503538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin's lymphoma: study of 200 patients.
    Batlle M; Ribera JM; Oriol A; Pastor C; Mate JL; Fernández-Avilés F; Flores A; Millá F; Feliu E
    Leuk Lymphoma; 2005 Oct; 46(10):1471-6. PubMed ID: 16194893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
    Albitar M; Vose JM; Johnson MM; Do KA; Day A; Jilani I; Kantarjian H; Keating M; O'Brien SM; Verstovsek S; Armitage JO; Giles FJ
    Leuk Res; 2007 Feb; 31(2):139-45. PubMed ID: 16545870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma.
    Bien E; Balcerska A
    Scand J Immunol; 2009 Nov; 70(5):490-500. PubMed ID: 19874554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic significance of CA 125 in patients with non-Hodgkin's lymphoma.
    Zacharos ID; Efstathiou SP; Petreli E; Georgiou G; Tsioulos DI; Mastorantonakis SE; Christakopoulou I; Roussou PP
    Eur J Haematol; 2002 Oct; 69(4):221-6. PubMed ID: 12431241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: significance of very high serum LDH concentrations.
    Tomita N; Kodama F; Sakai R; Koharasawa H; Hattori M; Taguchi J; Fujita H; Tanabe J; Fujisawa S; Fukawa H; Harano H; Kanamori H; Miyashita H; Matsuzaki M; Ogawa K; Motomura S; Maruta A; Ishigatsubo Y
    Leuk Lymphoma; 2000 Jul; 38(3-4):335-43. PubMed ID: 10830740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Validity of the International Prognostic Index in non-Hodgkin's lymphomas of varying grades of malignancy].
    Bettini R; Caronni F; Maino C; Marzetta K; Sala D; Saccà V; Gorini M
    Recenti Prog Med; 2003 Nov; 94(11):494-500. PubMed ID: 14679917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
    Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
    Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost determinants in aggressive non-Hodgkin's lymphoma.
    van Agthoven M; Sonneveld P; Verdonck LF; Uyl-de Groot CA
    Haematologica; 2005 May; 90(5):661-71. PubMed ID: 15921381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.